Tryp Therapeutics Inc.
Sep 22, 2021
Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating Disorders
Sep 16, 2021
Tryp Therapeutics to Present at Oppenheimer Fall Healthcare Summit
Sep 1, 2021
Tryp Therapeutics to Present at H.C. Wainwright Global Investment Conference
Aug 24, 2021
Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida
Aug 18, 2021
Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor
Aug 9, 2021
Tryp Therapeutics Partners with Calvert Labs to Conduct Exploratory Studies for Proprietary Psilocybin Formulations
Aug 3, 2021
Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference
Jul 28, 2021
Tryp Therapeutics Announces 3Q 2021 Financial Results
Jul 26, 2021
Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor
Jul 21, 2021
Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan
Jul 15, 2021
Tryp Therapeutics to Host Q3 Investor Day on July 29, 2021
Jul 7, 2021
Tryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary Formulations
Jun 1, 2021
Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference
May 25, 2021
Tryp Therapeutics Partners with Alcami for Proprietary Formulations
May 10, 2021
Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support
May 3, 2021
Tryp Therapeutics Partners with Fluence for Psychotherapy Design
Apr 29, 2021
Tryp Therapeutics Announces Q2 2021 Financial Results
Apr 20, 2021
Tryp Therapeutics Reports on Key Milestones for 2021
Apr 15, 2021
Tryp Therapeutics to Host Investor Day on April 22
Apr 5, 2021
Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility
Apr 1, 2021
Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer
Mar 18, 2021
Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics
Mar 9, 2021
Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer
Mar 4, 2021
Tryp Therapeutics Announces Application to List on OTCQB
Feb 24, 2021
Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference
Feb 18, 2021
Tryp Therapeutics Completes $2 Million Strategic Financing
Feb 16, 2021
Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program
Feb 11, 2021
Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor
Feb 8, 2021
Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller
Feb 5, 2021
Tryp Therapeutics Announces Strategic Investment of $2,000,000
Feb 3, 2021
Tryp Therapeutics Announces Appointment of Greg McKee as Executive Chairman
Feb 2, 2021
Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board
Jan 19, 2021
Tryp Therapeutics Invited to Present at "Investing in Psychedelics" Conference
Jan 13, 2021
Tryp Therapeutics Invited to Present at Global Healthcare & Psychedelic Conferences
Jan 13, 2021
Tryp Therapeutics Strengthens Board of Directors With Appointment of Gregory M. McKee
Jan 7, 2021
Tryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory Board

Please sign up to receive updates

© 2021
All rights reserved.
Disclaimer